Diana Brainard
Chief Executive Officer bei ALLOVIR, INC.
Vermögen: 625 160 $ am 31.03.2024
Aktive Positionen von Diana Brainard
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ALLOVIR, INC. | Director/Board Member | 01.07.2020 | - |
| Chief Executive Officer | 17.05.2021 | - | |
| Independent Dir/Board Member | 01.04.2019 | - | |
| NEKTAR THERAPEUTICS | Director/Board Member | 11.11.2021 | - |
| Independent Dir/Board Member | 11.11.2021 | - | |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Board Member | 08.03.2022 | - |
| Independent Dir/Board Member | 08.03.2022 | - | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - | - |
Karriereverlauf von Diana Brainard
Ehemalige bekannte Positionen von Diana Brainard
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.01.2015 | 01.01.2021 |
Ausbildung von Diana Brainard
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Diana Brainard
- Erfahrung
